Press releaseBusiness Wire
Bio Rad Laboratories
BIO · NYSE
$354.50+$1.68 (+0.48%)TodayMarket closed ·
Prev close $352.82
Latest news
- Press releaseBusiness Wire
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
- Press releaseBusiness Wire
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference
- Press releaseGlobe Newswire
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
- News
Bio-Rad Laboratories Q2 Adj. EPS $2.62 Beats $1.75 Estimate, Sales $651.000M Beat $623.989M Estimate
- Press releaseBusiness Wire
Bio-Rad Reports Second-Quarter 2026 Financial Results
- Press releaseBusiness Wire
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
- NewsVandana Singh
Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories
- NewsPiero Cingari
Nasdaq 100 Drops Over 1%, Oil Tops $106 On Iran Impasse: Stock Market Today
- NewsAvi Kapoor
Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday
- Press releaseBusiness Wire
Bio-Rad to Participate in Upcoming Investor Conferences
- NewsPiero Cingari
Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU
- News
Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call
- News
Bio-Rad Laboratories Q1 Adj. EPS $1.89 Misses $1.98 Estimate, Sales $592.100M Beat $588.875M Estimate
- Press releaseBusiness Wire
Bio-Rad Reports First-Quarter 2026 Financial Results
- Press releaseBusiness Wire
Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseBusiness Wire
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Press releaseBusiness Wire
Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
- NewsVandana Singh
Qiagen Explores Possible Sale After New Buyer Talks: Report
- Press releaseBusiness Wire
Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
- Press releaseBusiness Wire
Bio-Rad Reports Third-Quarter 2025 Financial Results
- Press releaseBusiness Wire
Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
- Press releaseBusiness Wire
Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away
- Press releaseBusiness Wire
Bio-Rad's Management to Participate in Upcoming Investor Conferences
- NewsAvi Kapoor
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
- Press releaseBusiness Wire
Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseBusiness Wire
Bio-Rad Reports Second-Quarter 2025 Financial Results
- Press releaseBusiness Wire
Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations
- Press releaseBusiness Wire
Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025
- Press releaseBusiness Wire
Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout
- Press releaseBusiness Wire
Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference
- Press releaseBusiness Wire
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
- Press releaseBusiness Wire
Bio-Rad Reports First-Quarter 2025 Financial Results
- Press releaseGlobe Newswire
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.